A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

985

Enrollment

INDUSTRY

Sponsor class

Conditions

Biochemically Recurrent Prostate Cancer

Interventions

DRUG: Darolutamide (BAY1841788, Nubeqa)
OTHER: Placebo matching darolutamide
OTHER: ADT

Sponsor

Bayer